Medtronic is a solid choice for dividend investors, but Intuitive Surgical is a better option for growth-oriented investors. Intuitive Surgical will continue dominating its niche even as Medtronic ...

ISLAMABAD: The Higher Education Commission (HEC) on Friday said it has initiated a project to revamp its degree attestation system by integrating cutting-edge blockchain technology. “This pivotal ...

"At some point here, we're going to get an opportunity to ask the fans, actually, what they [are interested in hearing]," he added. "We can kind of pick and choose through that and salt and pepper our ...

Heavy Metal fans have good news to share! Motley Crue, the 80’s band founded by bassist Nikki Six and drummer Tommy Lee with guitarist Mick Mars and lead vocalist Vince Neil, are alive, well and ...

Motley Crue began a residency in Las Vegas Friday night that was supposed to commence last March, and singer Vince Neil has now revealed the reason for the six-month delay: He suffered a debilitating ...

Mötley Crüe musician Vince Neil is opening up about his recovery after suffering a stroke. “I had to learn to walk again, and that was tough,” Neil, 64, told the Las Vegas Review-Journal in a Friday, ...

Mötley Crüe frontman Vince Neil is opening up about the major health scare that put the band on hold. Last Christmas, Neil suffered a stroke so severe his doctors didn't believe he'd be able to walk ...

Bain Capital agreed to sell its data centers in China to Shenzhen Dongyangguang Industry Co. in a transaction valued at about $4 billion. Shenzhen Dongyangguang, the parent of Shanghai-listed ...

Marking a historic milestone, the U.S. Coast Guard announced Monday the combined interdiction of more than 76,140 pounds of illicit narcotics. The quantity of drugs offloaded at Port Everglades is the ...

Johnson & Johnson is still facing many lawsuits that threaten its business. It may face additional challenges from patent cliffs and regulatory changes. Despite that, the drugmaker has important ...

Revolution Medicines has secured a potential funding infusion of up to $2 billion from Royalty Pharma in return for a slice of the profits if Revolution’s lead cancer drug makes it to market.